echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Research Frontiers What are the differences in the benefits of targeted therapy in elderly mRCC patients?

    Research Frontiers What are the differences in the benefits of targeted therapy in elderly mRCC patients?

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com




    Guide


    Has the last 20 years of medical technology improvements in overall survival (OS) for patients with metastatic renal cell carcinoma (mRCC) are still the same in the elderly population? The investigators conducted a retrospective study to assess whether such survival benefits also apply to elderly patients with mRCC.



    background


    The development and application of tyrosine kinase inhibition (TKI) and checkpoint inhibitors (CPI) have improved the prognosis of RCC, but elderly patients may be more sensitive to the chronic toxicity of these drugs, and in many phase III clinical trials, the proportion of patients ≥ 65 years old is only 30%-40%, while the median age of patients diagnosed with RCC is about 70 years, and the previous data are underrepresentative
    .
    Therefore, the investigators conducted this study to assess whether the OS benefit was consistent
    in older patients with these new regimens.


    Research methods


    The investigators retrospectively analyzed data
    from 401 mRCC patients treated at the Hannover Medical School from January 2003 to May 2016.
    The treatment period is divided into P1: 2003.
    01.
    01-2009.
    12.
    31;P2:2010.
    01.
    01-2016.
    05.
    31
    .
    Patients were divided into three groups according to age: ≤ 60 years old group (group 1), 60-75 years old group (group 2), > 75 years old group (group 3).

    Descriptive statistical analysis, Kaplan–Meier analysis, and Logistic regression analysis were used to evaluate
    the study data.


    Research results


    A total of 314 patient data were included in the final data analysis, of which 173 (55%) patients were treated in the P1 phase and 141 (45%) were treated
    in the P2 phase.
    The median follow-up was 33.
    8 months (range: 1-181.
    6 months) for the P1 phase and 27.
    3 months (range: 0.
    6-179.
    5 months)
    for the P2 phase.


    The median OS for the overall cohort was 39.
    7 months (95% CI 33.
    1 to 46.
    3 months); The median OS for P1 and P2 phases was 35.
    1 months (95% CI 28.
    3 to 41.
    9 months) and 59.
    1 months (95% CI 36.
    1 to 82.
    2 months, Log-rank:p=0.
    002),
    respectively.

     

    Fig.
    1 OS results at different treatment periods


    Analysis of patients in different age groups showed that the median OS was 38.
    1 months (95% CI 28.
    6 to 47.
    6 months) in Group 1, 42.
    9 months (95% CI 29.
    5 to 56.
    3 months) in Group 2, and 27.
    3 months (95% CI 12.
    8 to 41.
    8 months)
    in Group 3.
    There was no statistically significant
    difference between groups in OS.
    Comparing OS in different age groups and different treatment periods, it was found that patients in group 2 had the greatest improvement in OS, 59.
    1 months (95% CI 22.
    9-95.
    3 months) vs 40.
    1 months (95% CI 30.
    5-49.
    7 months), Log-rank p=0.
    034
    .
    A similar trend was observed in Group 3 (Log-rank p=0.
    056).

    Fig.
    2 OS results of P1 and P2 stages in different age groups (A: group 1; B: Group 2; C: Group 3)


    The results of multivariate analysis in stage 1 showed that age > 75 years (logistic regression p=0.
    002), histological non-ccRCC (logistic regression p=0.
    002), high MSKCC score (p=0.
    012), and ≥2 metastases (logistic regression p=0.
    018) were independent risk factors for
    OS 。 Multivariate analysis of Phase 2 showed that only ECOG PS≥1 (logistic regression p<0.
    001) affected OS<b11>.
    Therefore, the age factor in stage 2 cannot be recognized as increasing the risk
    of OS.


    Fig.
    3 Analysis of risk factors for death


    conclusion


    All age groups showed improvement in OS during the targeted therapy period, and older patients could also benefit from
    targeted therapies such as TKIs.
    Suitable older patients can also benefit
    from participating after being evaluated.


    References

    Eggers H, Schünemann C, Grünwald V, Rudolph L, Tiemann ML, Reuter C, Anders-Meyn MF, Ganser A, Ivanyi P.
    Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options? World J Urol.
    2022 Oct; 40(10):2489-2497.


    Edit: LR

    Review: LR

    Typesetting: LR

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.